Chlamydia Infections Pipeline, Therapies, Drugs, Clinical Trials Analysis Report 2021 | DelveInsight

Chlamydia Infections Pipeline, Therapies, Drugs, Clinical Trials Analysis Report 2021 | DelveInsight

“Chlamydia Infections Pipeline”

DelveInsight’s Chlamydia Infections Pipeline Insight report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Chlamydia Infections pipeline landscapes. It comprises Chlamydia Infections pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chlamydia Infections therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chlamydia Infections pipeline products.     


Some of the key takeaways from the Chlamydia Infections Pipeline Report  

  • Major companies such as Abera Bioscience AB, Spixia Biotechnology, Prokarium, QURETECH BIO, Evofem Biosciences, Abivax SA, Eurocine Vaccines AB, Genetic Immunity Inc., Vault Pharma, Yaso Therapeutics, and others are developing potential drug candidates to improve the Chlamydia Infections treatment scenario. 
  • EVO100 has been granted Fast Track Designation for Chlamydia prevention in women. It is designated a Qualified Infectious Disease Product (QIDP) to prevent gonorrhea in women by the U.S. Food and Drug Administration.
  • In September 2018, BlueWillow Biologics announced the company had been awarded an NIH Small Business Innovation Research (SBIR) grant to develop an intranasal NanoVax® vaccine to prevent chlamydia. More than 131 million new chlamydia infections worldwide each year, and no approved vaccine currently exists to prevent the infection.
  • QURETECH BIO is developing Chlamydia Infection Blockers. These are the Virulence blockers that can replace antibiotics for the treatment of chlamydia infections. They are currently in the preclinical stage of development.
  • In February 2021, Eurocine Vaccines AB (“Eurocine Vaccines”) confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate. The study demonstrates that an adapted variant of the vaccine, designed to meet the regulatory requirements for a finished product, is highly immunogenic. The good immunological effect of the tested vaccine surpasses, by a good margin, what in previous studies with our vaccine has protected in preclinical models.
  • On March 31, 2021, Eurocine Vaccines AB (“Eurocine Vaccines”) announced the completion of knowledge transfer and preparations for the development of the manufacturing process to secure the active protein needed in the toxicological and clinical studies with the company´s chlamydia vaccine candidate and the start of process development activities.
  • Genetic Immunity Inc. is developing ChlamyDerm Immune Therapy against Chlamydia infection that plays a role in atherosclerosis. They have demonstrated in mice the decrease of both inflammation and Chlamydia bacterium in the lung after ChlamyDerm immunization.
  • In March 2019, Yaso Therapeutics announced that the company had received a fifth SBIR grant from the National Institutes of Health (NIH), enabling the firm to complete preclinical testing of a novel polymer, PPCM contraceptive, multi-purpose prevention drug product.  Preclinical studies of PPCM indicate it is both contraceptive and can prevent various diseases, including herpes, gonorrhea, and chlamydia.  


Get an overview of pipeline landscape @ Chlamydia Infections Clinical Trials Analysis 


Chlamydia can infect both men and women. Chlamydial Infections are treated primarily by administering antibiotics such as Azithromycin, Doxycycline, Ofloxacin. 


Chlamydia Infections Emerging Drugs

  •  EVO100: Evofem Biosciences
  • Chlamydia Vaccine Candidate: Eurocine Vaccines AB

Eurocine Vaccines AB is developing a Chlamydia Vaccine Candidate. They have successfully identified sections of the MOMP (Major Outer Membrane Protein) in the bacterium Chlamydia trachomatis – sequences that can be used to stimulate an immune response. The specially designed protein chains are essential for the creation of the vaccine and are patent protected.

Research and DevelopmentInitial studies have proven the active protein to be very immunogenic and well-tolerated even without an adjuvant.Three major pre-clinical studies have been performed in mice, resulting in positive antibody and T-cell responses. The current development involves; 1) setting up an industrially scalable manufacturing process to ensure high-quality supply to future studies – 1st – 4th quarter 2021; 2) to manufacture study products for the planned clinical study according to GMP – 2nd quarter 2022; and 3) to design a Phase I clinical trial to be started in the fall of 2022.


For further information, refer to the detailed report @ Chlamydia Infections Pipeline Therapeutics


Scope of Chlamydia Infections Pipeline Drug Insight    

  • Coverage: Global 
  • Major Players: 10+ Key Players
  • Prominent Players: Abera Bioscience AB, Spixia Biotechnology, Prokarium, QURETECH BIO, Evofem Biosciences, Abivax SA, Eurocine Vaccines AB, Genetic Immunity Inc., Vault Pharma, Yaso Therapeutics
  • Key Drugs Profiles: 10+ Products


Key Questions regarding Current Chlamydia Infections Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

  • What are the current options for Chlamydia Infections treatment?
  • How many companies are developing therapies for the treatment of Chlamydia Infections? 
  • How many are Chlamydia Infections emerging therapies in the early-stage, mid-stage, and late development stages to treat Chlamydia Infections? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Chlamydia Infections market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Chlamydia Infections?  
  • What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Chlamydia Infections therapies? 
  • What are the critical designations that have been granted for the emerging therapies for Chlamydia Infections? 
  • How many patents are granted and pending for the emerging therapies to treat Chlamydia Infections?   


Table of Contents


Chlamydia Infections Report Introduction


Chlamydia Infections Executive Summary


Chlamydia Infections Overview


Chlamydia Infections – DelveInsight’s Analytical Perspective In-depth Commercial Assessment


Chlamydia Infections Pipeline Therapeutics


Chlamydia Infections Late Stage Products (Registered)


Chlamydia Infections Late Stage Products (Phase III)


EVO100: Evofem Biosciences


Chlamydia Infections Mid Stage Products (Phase II)


Chlamydia Infections Early Stage Products (Phase I)


Chlamydia Infections Pre-clinical and Discovery Stage Products


VPI-201: Vault Pharma


Chlamydia Infections Therapeutic Assessment


Chlamydia Infections Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Chlamydia Infections Key Companies


Chlamydia Infections Key Products


Chlamydia Infections Unmet Needs


Chlamydia Infections Market Drivers and Barriers


Chlamydia Infections Future Perspectives and Conclusion


Chlamydia Infections Analyst Views




About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States